Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV Outcomes Study for Chronic Kidney Disease and Type 2 Diabetes

May 11, 2021 Auto Bot Bayer, chronic kidney disease, Clinical Trials, finerenone, P-III 0

Shots:

  • The P-III FIGARO-DKD study involves assessing the efficacy and safety of finerenone (10/20mg, PO, qd) + SoC vs PBO + SoC in ~7400 patients with CKD and T2D at 1,000+ sites across 47 countries globally
  • The study resulted in meeting its 1EPs i.e reduction in the composite risk of time to the first occurrence of CV death and non-fatal CV events or outcomes in patients with CKD and T2D
  • The FDA currently reviews the NDA for Priority Review based on the P-III FIDELIO-DKD study while the data from the FIGARO-DKD study will be presented at an upcoming scientific meeting. Finerenone is an investigational non-steroidal, selective mineralocorticoid receptor antagonist

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: Bayer

The post Bayer Reports Results of Finerenone in P- III FIGARO-DKD CV Outcomes Study for Chronic Kidney Disease and Type 2 Diabetes first appeared on PharmaShots.